inducing hyperlipidemia to characterize diastolic dysfunction in hfpef mice

Hiperlipidemiye Bağlı Fare Modelinde HFpEF Patofizyolojisinin İncelenmesi

Heart failure with preserved ejection fraction (HFpEF) denotes a cardiometabolic syndrome accompanied by multiple comorbidities and constitutes over 50% of all heart failure cases1,2. Moreover, the frequency of HFpEF has steadily risen over the past decade3. With limited treatment options, HFpEF represents the most significant unmet medical necessity in cardiovascular disease, given its multifaceted pathophysiology4. Thus, an urgent need exists to enhance comprehension of the underlying mechanisms and pathophysiology of HFpEF to develop effective therapies.
Despite significant advancements in recent years, the pathophysiology of HFpEF attributed to lipotoxicity remains incompletely understood. It is established that patients with HFpEF exhibit notable myocardial lipid accumulation compared to those with heart failure with reduced ejection fraction (HFrEF) and healthy controls5. RNA sequencing data from cardiac biopsies showed downregulation of the lipoprotein lipase (LPL) gene in the HFpEF group compared to the healthy and HFrEF patients6. Poloxamer-407 (P-407) is a block co-polymer that induces hyperlipidemia by blocking LPL and subsequently increasing plasma triglycerides and low-density lipoprotein (LDL) cholesterol7. Previous studies demonstrated high LDL-Receptor (LDLR) expression in the hearts of HFpEF mice8. 
Building upon these findings and recognizing the pressing need for animal models accurately mimicking cardio-metabolic HFpEF, a hyperlipidemia-induced murine model was developed and presented. This model was tailored to explore HFpEF, explicitly focusing on the involvement of lipotoxicity alongside metabolic syndrome. Induced by hyperlipidemia/LPL blockade and enhanced cardiac LDLR expression, this model was established in WT-129 mice on 129J background through biweekly intraperitoneal (i.p.) injections of P-407 combined with a single intravenous (i.v.) injection of adeno-associated virus 9-cardiac troponin T-LDLR (AAV9-cTnT-LDLR)9.
Between 4 and 8 weeks post-treatment, an extensive array of assessments was conducted, encompassing echocardiography, blood pressure recordings, whole-body plethysmography (WBP), continuous electrocardiography (ECG) telemetry, activity wheel monitoring (AWM), as well as biochemical and histological analyses9. At four weeks, the LDLR/P407 or "double treatment" mice exhibited distinct HFpEF features, including diastolic dysfunction, preserved ejection fraction, and increased left ventricular wall thickness9. Additionally, ECG telemetry and AWM revealed heart blocks and reduced activity, respectively. Notably, blood pressure and renal function remained normal9. By eight weeks, diastolic function deteriorated, and WBP measurements unveiled reduced respiratory rates9. 
Further exploration of the double treatment model revealed fibrosis, elevated wet/dry lung ratios, and heart weight/body weight ratios9. Necropsy revealed ascites, cardiac ischemia, and xanthelasmas. Intriguingly, sudden deaths were documented between 6 and 12 weeks post-treatment9. This murine hyperlipidemia-driven HFpEF model provides a rapid, valuable, and promising experimental tool for unraveling the complexities of metabolic syndrome contributing to diastolic dysfunction with lipotoxicity-mediated HFpEF.

Yazar Spotlight: Lipotoksisite ve HFpEF Arasındaki İlişkiyi Keşfetmek 

Korunmuş Ejeksiyon Fraksiyonu ile Hiperlipidemiye Bağlı Kalp Yetmezliğinin Murin Modeli

Our research aims at examining heart failure with preserved ejection fraction, known as HFpEF, specifically investigating the effects of lipotoxicity. We seek to elucidate the intricate relationship between metabolic syndrome and lipotoxicity in driving HFpEF progression and uncover the underlying mechanisms driving HFpEF pathophysiology using this experimental murine model. Despite the rising prevalence and limited treatment options for HFpEF, its pathophysiological mechanisms mainly related to metabolic syndrome remain poorly understood.This model presents a unique opportunity to bridge this gap and potentially develop new therapies for HFpEF. Our model's most important advantage is its ability to mimic significant lipid mishandling observed in HFpEF patients. This mouse model offers valuable insights into the pathophysiology of HFpEF, especially cardiac metabolism.Our findings underscore the importance of fatty acid and cholesterol mishandling in cardiometabolic HFpEF. This model perfectly shows how fatty acid deprivation disrupts metabolism at different levels. It provides researchers with potential avenues to discover novel traps for HFpEF patients.Here at the Shahada Laboratory, we will focus on translating this model into large animals. We will investigate questions related to the pathogenesis, sudden death, and potential therapeutic interventions targeting lipotoxicity, inflammation, and cardiac remodeling.

HFpEF Farelerinde Diyastolik Disfonksiyonu Karakterize Etmek için Hiperlipidemiyi İndüklemek

Başlamak için, viral vektör stok şişelerini 20 dakika boyunca buz üzerinde çözün ve AAV parçacıklarını 100 mikrolitre DPBS ile seyreltin. Seyreltilmiş AAV solüsyonunu, hava kabarcıklarını önleyerek 28 ila 30 gauge iğne ile bir mililitrelik bir şırıngaya yükleyin. Anestezi uygulanmış fareyi bir kuyruk aydınlatıcı tutucuya sabitleyin.Enjeksiyon bölgesini antiseptik ile temizlemek için bir gazlı bez kullanın. Damar görülene kadar kuyruğa iki parmağınızla masaj yapın. Daha sonra vektörü kuyruk damarına düşük bir açıyla enjekte edin ve iğneyi geri çekin.Kanamayı durdurmak için bir parmağınızı kullanarak enjekte edilen bölgeye hemen baskı uygulayın. Poloksamer 407'yi hazırlamak için, bir biyo güvenlik kabininde gece boyunca dört santigrat derecede bir döndürücü üzerinde DPBS'de çözün. Ardından, fareyi bir çeker ocak altında manuel olarak tutun, başını ve gövdesini aşağı doğru konumlandırın.Bir antiseptik ile, orta hatta lateral karnın sol alt çeyreğindeki enjeksiyon bölgesini temizleyin. P407'yi enjekte etmek için, iğneyi periton boşluğuna 45 derece veya daha az bir açıyla yerleştirin. Dört haftalık hiperlipidemi indüksiyonundan sonra ekokardiyografide intraventriküler gevşeme süresi uzadığı için ejeksiyon fraksiyonu korunmuş kalp yetmezliği saptandı.Erken mitral yağsız akım hızı ile mitral anüler erken diyastolik hız arasında artmış bir oran gözlenirken, erken ve geç diyastolik trans mitral akım hızında azalma gözlendi.

inducing-hyperlipidemia-to-characterize-diastolic-dysfunction-hfpef

Research

JoVE Journal

Medicine

Inducing Hyperlipidemia to Characterize Diastolic Dysfunction in HFpEF Mice

322 Görüntüleme.  University of Miami Leonard M. Miller School of Medicine. Başlamak için, viral vektör stok şişelerini 20 dakika boyunca buz üzerinde çözün ve AAV parçacıklarını 100 mikrolitre DPBS ile seyreltin. Seyreltilmiş AAV solüsyonunu, hava kabarcıklarını önleyerek 28 ila 30 gauge iğne ile bir mililitrelik bir şırıngaya yükleyin. Anestezi uygulanmış fareyi bir kuyruk aydınlatıcı tutucuya sabitleyin.Enjeksiyon bölgesini antiseptik ile temizlemek için bir gazlı bez kullanın. Damar görülene kadar kuyruğa iki parmağın?...

Video: HFpEF Farelerinde Diyastolik Disfonksiyonu Karakterize Etmek için Hiperlipidemiyi İndüklemek

A Murine Model of Hyperlipidemia&#45;Induced Heart Failure with Preserved Ejection Fraction

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) driven by lipotoxicity is incompletely understood. Given the urgent need for animal models that accurately mimic cardio-metabolic HFpEF, a hyperlipidemia-induced murine model was developed by reverse engineering phenotypes seen in HFpEF patients. This model aimed to investigate HFpEF, focusing on the interplay between lipotoxicity and metabolic syndrome. Hyperlipidemia was induced in wild-type (WT) mice on a 129J strain background through bi-weekly intraperitoneal injections of poloxamer-407 (P-407), a block co-polymer that blocks lipoprotein lipase, combined with a single intravenous injection of adeno-associated virus 9-cardiac troponin T-low-density lipoprotein receptor (AAV9-cTnT-LDLR). Extensive assessments were conducted between 4 and 8 weeks post-treatment, including echocardiography, blood pressure recording, whole-body plethysmography, echocardiography (ECG) telemetry, activity wheel monitoring (AWM), and biochemical and histological analyses. The LDLR/P-407 mice exhibited distinctive features at four weeks, including diastolic dysfunction, preserved ejection fraction, and increased left ventricular wall thickness. Notably, blood pressure and renal function remained within normal ranges. Additionally, ECG and AWM revealed heart blocks and reduced activity, respectively. Diastolic function deteriorated at eight weeks, accompanied by a significant decline in respiratory rates. Further investigation into the double treatment model revealed elevated fibrosis, wet/dry lung ratios, and heart weight/body weight ratios. The LDLR/P-407 mice exhibited xanthelasmas, ascites, and cardiac ischemia. Interestingly, sudden deaths occurred between 6 and 12 weeks post-treatment. The murine HFpEF model offers a valuable and promising experimental resource for elucidating the intricacies of metabolic syndrome contributing to diastolic dysfunction within the context of lipotoxicity-mediated HFpEF.

This protocol presents a detailed approach to replicating a murine model of hyperlipidemia-induced heart failure with preserved ejection fraction (HFpEF). The design combines the administration of adeno-associated virus 9-cardiac troponin T-low-density lipoprotein receptor (AAV9-cTnT-LDLR) and poloxamer-407 (P-407).

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) driven by lipotoxicity is incompletely understood. Given the urgent need for ...